Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy ...
BOSTON - Praxis Precision Medicines Inc. (NASDAQ: PRAX) announced that the Independent Data Monitoring Committee (IDMC) has recommended halting Study 1 of the Essential3 program, which is evaluating ...
BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
TipRanks on MSN
Praxis wins FDA breakthrough status for ulixacaltamide
The latest announcement is out from Praxis Precision Medicines ( ($PRAX) ). On December 29, 2025, Praxis Precision Medicines, Inc. reported that ...
Praxis Precision Medicines surged after positive Essential3 data for ulixacaltamide in essential tremor, but tolerability issues limit enthusiasm. Ulixacaltamide demonstrated functional benefit, but ...
Praxis Precision Medicines’ commitment to forging ahead with ulixacaltamide in essential tremor (ET) has paid off. After brushing off a recommendation to end a phase 3 study earlier this year based on ...
Hosted on MSN
Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing.
Shares of biopharmaceutical company Praxis Precision Medicines Inc. soared Thursday, boosted by the successful trial of a new drug to treat movement disorders. The drug, ulixacaltamide, targets ...
A committee of outside clinical trial observers has recommended that Praxis Precision Medicines stop testing its experimental treatment for essential tremor after an interim analysis of one study ...
Praxis Precision Medicines is converting its EMBRAVE3 study of elsunersen for children suffering from a developmental disease into a single-arm study after meeting with the Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback